Navigation Links
Tethys Bioscience Hits Key Milestones With Series C Funding, Opening of CLIA Laboratory

Biomarker discovery company builds strong financial and clinical foundation in preparation for release of technology enabling early detection of risk

for diabetes

EMERYVILLE, Calif., Jan. 10 /PRNewswire/ -- Tethys Bioscience today announced that it has reached two significant milestones in its drive to release Tethys Diabetes PreDxTM, a multi-biomarker technology that provides a more complete picture of an individual's future risk of developing diabetes. The company received its latest round of funding (Series C), and also received the licensing of its CLIA Lab by the State of California. Both moves place Tethys Bioscience in a strong position to establish itself as a leader in the emerging field of personalized predictive medicine and to achieve its goal of helping to stem the burgeoning epidemic of chronic, high-burden metabolic disease. Tethys Diabetes PreDxTM will be generally available in the first half of 2009.


The new round of funding is led by Intel Capital, which was created specifically to invest in innovation and has a strong interest in the emerging field of predictive personalized medicine. This latest financing, a process begun with earlier investments from some of the leading venture capital firms, including Kleiner Perkins Caufield & Byers and MDV-Mohr Davidow Ventures, results in a total of $54 million in financing, to date.

"We're very pleased to receive this round of financing from our investors, and believe it supports our vision to dramatically improve the detection and treatment, and ultimately prevention, of chronic diseases," said Mickey Urdea, CEO of Tethys Bioscience. "It gives us the resources to accelerate our work in this critical field, and to introduce a technology that enables a clinically simple blood test that provides an objective means to identify individuals at highest risk for diabetes. Our test will give medical professionals, and their patients, the opportunity to intervene and modify the risk before irreversible damage occurs.

Tethys Bioscience also announced the licensing of its clinical lab by the State of California. This marks a significant step forward for the company, enabling it to make its testing services available for sale and to offer test results obtained in Tethys' own laboratory, where the technology was also developed.

There is a very large market for early detection technology enabling personalized preventive efforts in diabetes and other chronic diseases. It is estimated that up to 7% of the population, or nearly 21 million people, have diabetes, with more than six million of those currently undiagnosed. Further, the number of individuals at risk for diabetes is estimated to be greater than double the number of those with diabetes. Tethys Diabetes PreDxTM involves a simple to administer blood test, which fits easily into current clinical practice and provides clinically important, personalized risk information -- while matching or outperforming traditional clinical risk scores and measures of glucose dysregulation or insulin resistance. About Tethys BioscienceTethys Bioscience is dedicated to the discovery, development and commercialization of novel biological markers -- biomarkers -- that provide a practical tool to address the growing global healthcare challenge of chronic metabolic diseases such as diabetes. Tethys Bioscience comes to market with a unique combination: management, research, and commercialization teams with extensive experience in diagnostic innovation, strategic alliances with world-class researchers and partners, and a solid financial foundation to help transform the management of chronic diseases with personalized, preventive solutions that aid every constituency: patients, doctors, and the healthcare system as a whole.

SOURCE MDV-Mohr Davidow Ventures
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Ardea Biosciences Lead NNRTI for HIV, RDEA806, to Enter Phase 2a Proof-of- Concept Clinical Trial
2. Sangamo BioSciences Provides Update on Companys Accomplishments in 2007 and 2008 Objectives
3. Connecticut Bioscience Achievement Awards Presented at CURE Annual Meeting
4. SuperArray Bioscience Corporation Licenses RNA Interference Patent From The Carnegie Institution
5. Regado Biosciences to Present at 19th Annual Piper Jaffray Health Care Conference
6. KGI and Smith College Announce Speakers for Women Leadership Forum in Bioscience
7. Schering-Plough Receives Clearance From U.S. Federal Trade Commission for Planned Acquisition of Organon Biosciences N.V.
8. Pressure BioSciences, Inc. Reports Third Quarter 2007 Financial Results and Provides Business Update
10. Anaptys Biosciences Raises Over $33 Million in Series B Financing
11. Monogram Biosciences to Present at The Lazard Capital Markets Fourth Annual Healthcare Conference
Post Your Comments:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... established the certification process to promote standards of excellence for the field of ... scheduled for March 22 – 25, 2018 in Orlando, Florida at the Omni ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers care ... have a waiver for care if the client has a cognitive impairment diagnosis. ... for care, is often waived, so the benefits from their insurance start immediately,” said ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor Rob Lowe, ... in a new episode of "Success Files," which is an award-winning educational program ... investigates each subject in-depth with passion and integrity. , Sciatica occurs when the ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... treating sleep apnea using cutting-edge Oventus O2Vent technology. As many as ... disorder characterized by frequent cessation in breathing. Oral appliances can offer significant relief ...
(Date:10/12/2017)... ... , ... Asante, a nationally recognized health system in southern ... home health joint venture through an agreement, effective October 1, 2017, to create ... health company with Asante, delivering clinically integrated care, for the past eight years. ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... their devotion to personalized service, SMP Pharmacy Solutions announces their ... South Florida Business Journal,s 50 Fastest-Growing Companies, and listed for ... specialty pharmacy has found its niche.  To that end, the ... by SFBJ as the 2017 Power Leader in Health Care. ... award in October, Bardisa said of the three achievements, "It,s ...
(Date:9/23/2017)... HORSHAM, Pa. , Sept. 22, 2017 ... received a complete response letter from the U.S. Food ... (BLA) seeking approval of sirukumab for the treatment of ... response letter indicates additional clinical data are needed to ... of moderately to severely active RA. ...
(Date:9/19/2017)... 19, 2017   ZirMed Inc ., a recognized leader ... that it has been ranked #1 by its users for ... Rankings 2017 User Survey. ZirMed was recognized as the top-ranked ... and medical centers over 200 beds and holds one of ... user survey history. ...
Breaking Medicine Technology: